Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

Novo Nordisk A/S1,613 enrolled

Overview

This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.

Study Type

OBSERVATIONAL

Enrollment

1,613

Conditions

Menopause Postmenopausal Vaginal Atrophy

Interventions

estradiol, 25 mcgDRUG

Vaginal tablets for 6-12 weeks according to product labelling

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Atrophic vaginitis due to estrogen deficiency * Post-menopausal

Locations (1)

Novo Nordisk Investigational Site

Mainz, Germany

Outcomes

Primary Outcomes

Percentage of subjects reporting vaginal symptoms occuring 'often' and 'frequently'

Percentage of subjects reporting 'moderate' and 'severe' vaginal symptoms

Secondary Outcomes

Adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.